LDCT Screening for Lung Cancer? This Aid Can Help Decide
Web-based decision tool in development to help high-risk patients decide if they want to undergo low dose CT screening for lung cancer.
A web-based decision-making tool for lung cancer screening (LCS) may help patients at high risk for lung cancer from smoking, say researchers from the University of Kentucky and the University of Miami.
While the National Lung Screening Trial (NLST) found that low-dose CT screening (LDCT) among people at high risk for lung cancer showed a 20 percent relative reduction in lung cancer mortality as compared to chest radiography, the report also noted substantial risks and limitations to LDCT, which include overdiagnosis and high false positive rates. The concern now is that patients may not be properly equipped to decide for or against LCS. The researchers’ proposed project is to develop a web-based decision aid that will help patients decide whether to undergo LCS.
“Screening is for asymptomatic healthy people to find out there’s something wrong,” Jamie Studts, PhD, researcher at the University of Kentucky, said in a release. “You are committing to a series of events that will lead to either learning you don’t have cancer, or detecting it and treating it.”[[{"type":"media","view_mode":"media_crop","fid":"26735","attributes":{"alt":"low dose lung CT","class":"media-image media-image-right","id":"media_crop_7067090008529","media_crop_h":"0","media_crop_image_style":"-1","media_crop_instance":"2526","media_crop_rotate":"0","media_crop_scale_h":"0","media_crop_scale_w":"0","media_crop_w":"0","media_crop_x":"0","media_crop_y":"0","style":"height: 142px; width: 150px; border-width: 0px; border-style: solid; margin: 1px; float: right;","title":" ","typeof":"foaf:Image"}}]]
The decision-making aid will provide information to the patients and empower the patients to talk to their physicians and make their decisions with the relevant information. A third objective involves clarifying the patient’s values: their personal preferences regarding screening and treatment. “The goal is to help people interpret what they learn in the context of what’s important to them regarding their goals in health,” Studts said. “They will learn about lung cancer screening options, benefits, harms, and uncertainties associated with the modality.”
A clinical trial for the decision aid will be held in Florida and Kentucky.
Photon-Counting Computed Tomography: Eleven Takeaways from a New Literature Review
May 27th 2025In a review of 155 studies, researchers examined the capabilities of photon-counting computed tomography (PCCT) for enhanced accuracy, tissue characterization, artifact reduction and reduced radiation dosing across thoracic, abdominal, and cardiothoracic imaging applications.
Can AI Predict Future Lung Cancer Risk from a Single CT Scan?
May 19th 2025In never-smokers, deep learning assessment of single baseline low-dose computed tomography (CT) scans demonstrated a 79 percent AUC for predicting lung cancer up to six years later, according to new research presented today at the American Thoracic Society (ATS) 2025 International Conference.
Can Emerging AI Software Offer Detection of CAD on CCTA on Par with Radiologists?
May 14th 2025In a study involving over 1,000 patients who had coronary computed tomography angiography (CCTA) exams, AI software demonstrated a 90 percent AUC for assessments of cases > CAD-RADS 3 and 4A and had a 98 percent NPV for obstructive coronary artery disease.
